PAQ Therapeutics Announces $39 Million Series B Financing and Initiates Phase 1 Trial to Advance Novel Approach Addressing KRAS-Driven Cancers with High Unmet Need
–Series B co-led by MRL Ventures Fund (MRLV) and Bayland Capital, with participation from Johnson & Johnson Innovation – JJDC Inc., LAV Fund, BioTrack Capital, and Sherpa Health Partners– –First patient dosed in Phase 1 clinical…